|  | 
|  |  | 
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. | 
|   
 
    
    
    
A plausible strategy for investing in biotechs is to find those companies that have recently gone public and that are practising good science and business, but which have been beaten down due to the selling -- real or anticipated -- of insiders when the lock-up periods expire.  Given the huge financing bubble in 2000, there are many targets to screen. This thread is dedicated to finding the overly punished, and a portfolio will be assembled based on contributors' picks and polite discussion thereof. If the unlock is large, best to swing or position trade these babies. And why not short those doomed to fall while we're at it? If the unlock isn't too bad, or has already been worked through somewhat, maybe buy and hold for a while. This portfolio was started with $100K. For newbies to the SI biofreak style of portfolio management, here's how to interpret portfolio performance based on the bottom line numbers: Take Total Cost and subtract 100,000. Then add(subtract) the Total Gain/Loss. Replace the comma with a period and tack a percent sign on the end. Presto! You have the actual performance since inception. As I type, the example is: 111,093 - 100,000 - 5,862 ===> 5.231%. Cheers, Tuck | ||||||||||||
| 
 
 | 
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings | 
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI | 
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |